Intarcia Archives

News and Trends 23 Feb 2018

Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take the drug. After obtaining approval for an injected version, Novo Nordisk is now getting ready […]

February 23, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 15 Sep 2017

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […]

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Jan 2017

Fresh Cash for a Device that Can Treat Diabetes and Prevent HIV

Intarcia will develop a drug delivery device for HIV prevention that can significantly reduce dosing frequency, backed by a €134M ($140M) deal with the Bill & Melinda Gates Foundation. Intarcia is a biotech unicorn from the US with an innovative drug delivery system that has managed to attract €197M ($206M) in Series EE, including €48M ($50M) from […]

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

diabetes glucose chronic disease biotech pharma review

News and Trends 14 Jun 2016

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Given the rates of diabetes reaching ‘epidemic proportions’, we figured it was time to have a better overview of biotech’s progress in the field. With some serious advances having been made in the treatment of the disease, we have to ask – how much further can biotech go in the treatment of diabetes? It is important […]

June 14, 2016 - 9 minutesmins - By Dani Bancroft

numab intarcia antibodies implantable drug delivery

News and Trends 6 Jun 2016

Swiss-US Implant could make taking pills obsolete in Autoimmune Diseases

Numab and Intarcia have achieved key milestones in the development of therapeutic antibody fragments. This collaboration could span the next generation of implantable drug delivery tech for diabetes, obesity and autoimmune diseases. Based in Wädenswill (near Zurich), Numab is developing antibody-based therapeutics. With its ultra-high throughput technology, it can find rare molecules with big therapeutic potential that are […]

June 6, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 18 Sep 2015

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Treatment of diabetes hasn’t changed so much since the development of first human insulin by Genentech. But Boston-based Intarcia (a partner of Servier and one of the 9 billion-dollar Biotech startups worldwide) has just published positive phase III results of its implantable device aiming at changing how type 2 diabetes are treated. November 2014: I thought […]

September 18, 2015 - 3 minutesmins - By Philip Hemme

future biomarkers immuno oncology lymphocytes

News and Trends 31 Aug 2015

Review: The Future of Biomarkers in Immuno-Oncology

Immuno-oncology is a Biotech field that is more than just hype – it could solve one of humanity’s biggest health challenges: Cancer. In order to bring more effective treatments with fewer side-effects, Biomarkers will play a key role. I wanted to get an expert view on the subject, so I called Bernhard Sixt, CEO of the […]

August 31, 2015 - 5 minutesmins - By Philip Hemme

Intarcia Platform Technology deal Servier

News and Trends 15 Nov 2014

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

The French company Servier wants to invest one billion euros by a partnering with the American company Intarcia regarding their subcutaneous implant for diabetes. This is a breakthrough micropump, the first device without injection able to deliver the molecule Exenatide during one year. It is a huge step forward in treating type 2 diabetes. Indeed, most people forget […]

November 15, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Intarcia

Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Fresh Cash for a Device that Can Treat Diabetes and Prevent HIV

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Swiss-US Implant could make taking pills obsolete in Autoimmune Diseases

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Review: The Future of Biomarkers in Immuno-Oncology

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!